Quality of life and Comprehensive Geriatric Assessment (CGA) in older adults receiving Accelerated Partial Breast Irradiation (APBI) using a single fraction of Multi-Catheter Interstitial High-Dose Rate Brachytherapy (MIB). The SiFEBI phase I/II trial

Boulahssass, Rabia; Chand, Marie-Eve; Gal, Jocelyn; Dittlot, Claire; Schiappa, Renaud; Rambaud, C.; Gonfrier, Sébastien; Guérin, Olivier; Hannoun-Lévi, J.-M.

doi:10.1016/j.jgo.2021.04.009

Cited by 10 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The characteristics of the included studies are shown in Table A1 . There were 13 studies that conducted CGA pre-treatment [ 12 , 13 , 14 , 15 , 16 , 17 , 18 ] and six studies that conducted CGA post-treatment [ 19 , 20 , 21 , 22 , 23 ]. A total of 17 studies included patients >65 years of age or older.…”

Section: Resultsmentioning

confidence: 99%

“…The studies were categorised into four main themes based on their aim: (1) to determine factors influencing survival or mortality, which comprised five papers [ 12 , 13 , 14 , 15 , 19 ], (2) as an adjunct to treatment decision-making, which comprised six papers [ 16 , 17 , 20 , 21 , 22 , 23 ] (3) to measure quality of life and functional status, which comprised four papers [ 18 , 24 , 25 , 26 ], and (4) to determine which tools should be used in CGA, which comprised three papers [ 27 , 28 , 29 ]. Further discussion about the findings of studies and future directions are highlighted in Table A3 .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Comprehensive Geriatric Assessment for Older Women with Early-Stage (Non-Metastatic) Breast Cancer—An Updated Systematic Review of the Literature

Reid-Agboola,

Klukowska,

Malcolm

et al. 2023

Current Oncology

View full text Add to dashboard Cite

Background: A previous systematic review by our team (2012) undertook comprehensive geriatric assessment (CGA) in breast cancer and concluded there was not sufficient evidence to instate CGA as mandatory practice. SIOG/EUSOMA guidelines published in 2021 advocate the use of CGA in breast cancer patients. The aim is to perform an updated systematic review of the literature. Methods: A systematic review of studies published between 2012 and 2022 that assessed the use of CGA in breast cancer was performed on Cochrane, PubMed and Embase. Results: A total of 18 articles including 4734 patients with breast cancer were identified. The studies covered four themes for use of CGA in breast cancer: (1) to determine factors influencing survival (2) as an adjunct to treatment decision-making (3) to measure quality of life, and (4) to determine which tools should be included. There was evidence to support the use of CGA in themes 1–3; however, it is uncertain which assessment tools are best to use (theme 4). Conclusions: CGA can be used to determine factors affecting survival and quality of life in breast cancer patients and can therefore be used to aid treatment decision-making. Further work is required to determine gold standard CGA.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Comprehensive Geriatric Assessment for Older Women with Early-Stage (Non-Metastatic) Breast Cancer—An Updated Systematic Review of the Literature

Reid-Agboola,

Klukowska,

Malcolm

et al. 2023

Current Oncology

View full text Add to dashboard Cite

show abstract

“…59 Brachytherapy is an alternative to EBRT APBI and can be performed using interstitial catheters or applicator-based devices. The original modern RCT evaluating APBI utilized interstitial/electron APBI (36.4 Gy/7 fractions) compared [80][81][82] Applicator brachytherapy represents an alternative to interstitial brachytherapy; this technique was included in NSABP B-39, but no randomized trial has evaluated this technique exclusively. However, the MammoSite prospective registry evaluated 1449 patients treated with a singlelumen brachytherapy applicator (34 Gy/10 fractions, twice daily); 5-year outcomes demonstrated a 3.8% rate of local recurrence with 91% excellent/good cosmesis; toxicity profiles were also low, with a 14.8% rate of noninfectious complications at 1 year.…”

Section: Ultrashort Partial Breast Irradiationmentioning

confidence: 99%

Delivery of Adjuvant Radiation in 5 Days or Less After Lumpectomy for Breast Cancer: A Systematic Review

Vicini

Broughman

Halima

et al. 2022

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Single-fraction high-dose brachytherapy dose delivered ranged between 16 and 21 Gy. Median ages of patients treated ranged from 64 to 77 years, and included patients with early-stage breast cancer [18][19][20][21][22][23][24].…”

Section: Breastmentioning

confidence: 99%

“…The most significant study reported was a randomized controlled trial of single-fraction 19 Gy vs. two fractions of 13.5 Gy [ 18 ]. This study included 170 patients with either low- or intermediate-risk, with no prior androgen deprivation therapy.…”

Section: Prostatementioning

confidence: 99%

Single-fraction high-dose-rate brachytherapy: a scoping review on outcomes and toxicities for all disease sites

Kazemi¹,

Nadarajan²,

Kamrava³

2022

jcb

View full text Add to dashboard Cite

Purpose: Brachytherapy is well positioned to safely deliver highly conformal single-fraction doses of radiation, which can lower costs and improve efficiency. Traditionally, high-dose-rate brachytherapy (HDR-BT) has been delivered over multiple treatments. A scoping literature review was conducted to better understand the available literature on single-fraction HDR-BT for all disease sites.Material and methods: According to preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, PubMed database was queried from 1994-2021 using the following search terms: 'brachytherapy', 'highdose-rate', and 'single-fraction'. A total of 53 studies met our exclusion criteria.Results: Liver had the highest number of studies, with a total of 618 patients treated with doses ranging from 8 to 25 Gy. Median follow-up ranged from 11-33 months. Local control (LC) rates ranged from 37% to 98%. G3 acute/late toxicities or higher were reported in 3 patients. Prostate cancer included a total of 1,474 patients treated with doses ranging from 19 to 21 Gy. Median follow-up ranged from 20 to 72 months. Prostate specific antigen (PSA) control outcomes after definitive treatment ranged from 65% to 94%, and salvage treatments from 5% to 84%. G3 acute/late toxicities or higher ranged from 0 to 6%. Breast cancer included a total of 268 patients treated with doses ranging from 16 to 20 Gy. Median follow-up ranged from 24 to 72 months. LC rates were 100%. G3 acute toxicities or higher ranged from 0 to 6%. Regarding other cancers, conclusions were limited given the small number of patients within each respective site.Conclusions: Currently used regimens appear safe, but efficacy vary by different disease sites. Outcomes are more promising for breast and liver, while are less encouraging for prostate. Additional prospective evaluation of single-fraction HDR-BT regimens are warranted.

show abstract

Quality of life and Comprehensive Geriatric Assessment (CGA) in older adults receiving Accelerated Partial Breast Irradiation (APBI) using a single fraction of Multi-Catheter Interstitial High-Dose Rate Brachytherapy (MIB). The SiFEBI phase I/II trial

Cited by 10 publications

References 34 publications

Comprehensive Geriatric Assessment for Older Women with Early-Stage (Non-Metastatic) Breast Cancer—An Updated Systematic Review of the Literature

Comprehensive Geriatric Assessment for Older Women with Early-Stage (Non-Metastatic) Breast Cancer—An Updated Systematic Review of the Literature

Delivery of Adjuvant Radiation in 5 Days or Less After Lumpectomy for Breast Cancer: A Systematic Review

Single-fraction high-dose-rate brachytherapy: a scoping review on outcomes and toxicities for all disease sites

Contact Info

Product

Resources

About